{"id":560506,"date":"2026-07-10T14:49:13","date_gmt":"2026-07-10T12:49:13","guid":{"rendered":"https:\/\/medizinonline.com\/le-retatrutide-et-le-programme-triumph-le-triple-agoniste-en-passe-detre-commercialise\/"},"modified":"2026-07-10T18:00:31","modified_gmt":"2026-07-10T16:00:31","slug":"le-retatrutide-et-le-programme-triumph-le-triple-agoniste-en-passe-detre-commercialise","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/le-retatrutide-et-le-programme-triumph-le-triple-agoniste-en-passe-detre-commercialise\/","title":{"rendered":"Le Retatrutid et le programme TRIUMPH : le triple agoniste en passe de voir le jour"},"content":{"rendered":"\n

Le traitement de l\u2019ob\u00e9sit\u00e9 \u00e0 base d\u2019incr\u00e9tines a connu une \u00e9volution fulgurante en l\u2019espace de quelques ann\u00e9es : des agonistes des r\u00e9cepteurs du GLP-1 (s\u00e9maglutide) au tirz\u00e9patide, agoniste double GIP\/GLP-1, en passant par un agoniste triple. <\/em>Le r\u00e9tatrutide (LY3437943) active simultan\u00e9ment, en une seule mol\u00e9cule, trois r\u00e9cepteurs : ceux du polypeptide insulinotrope d\u00e9pendant du glucose (GIP), du peptide analogue au glucagon de type 1 (GLP-1) et du glucagon. Cette \u00e9volution s\u2019inscrit dans une logique plausible : \u00e0 chaque m\u00e9canisme d\u2019action suppl\u00e9mentaire, la perte de poids moyenne a augment\u00e9 dans les \u00e9tudes \u2013 du GLP-1 seul au GLP-1 associ\u00e9 au GIP, puis \u00e0 la triple combinaison. Le r\u00e9tatrutide est \u00e0 ce jour le repr\u00e9sentant le plus avanc\u00e9 de cette nouvelle classe et a suscit\u00e9 un vif int\u00e9r\u00eat en 2025\/2026 avec la publication des premiers r\u00e9sultats de phase III du programme TRIUMPH.<\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Le traitement de l\u2019ob\u00e9sit\u00e9 \u00e0 base d\u2019incr\u00e9tines a connu une \u00e9volution fulgurante en l\u2019espace de quelques ann\u00e9es : des agonistes des r\u00e9cepteurs du GLP-1 (s\u00e9maglutide) au tirz\u00e9patide, agoniste double GIP\/GLP-1,……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":560231,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Cardiom\u00e9tabolisme","footnotes":""},"category":[11549,11378,11404,11527,11531,11315,11410,11482],"tags":[95569,17458,72440,95571,95570],"powerkit_post_featured":[],"class_list":["post-560506","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-cardiologie","category-endocrinologie-et-diabetologie","category-etudes","category-formation-continue","category-medecine-interne-generale","category-nutrition-fr","category-prevention-et-soins-de-sante","tag-retatrutid","tag-semaglutid-fr","tag-tirzepatide-fr","tag-triple-agoniste","tag-triumph","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-20 04:44:18","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":560867,"slug":"retatrutid-e-il-programma-triumph-il-triplo-agonista-in-fase-di-sviluppo","post_title":"Retatrutid e il programma TRIUMPH: il triplo agonista in fase di sviluppo","href":"https:\/\/medizinonline.com\/it\/retatrutid-e-il-programma-triumph-il-triplo-agonista-in-fase-di-sviluppo\/"},"pt_PT":{"locale":"pt_PT","id":560870,"slug":"o-retatrutid-e-o-programa-triumph-o-agonista-triplo-em-fase-de-desenvolvimento","post_title":"O Retatrutid e o programa TRIUMPH: o agonista triplo em fase de desenvolvimento","href":"https:\/\/medizinonline.com\/pt-pt\/o-retatrutid-e-o-programa-triumph-o-agonista-triplo-em-fase-de-desenvolvimento\/"},"es_ES":{"locale":"es_ES","id":560873,"slug":"retatrutid-y-el-programa-triumph-el-agonista-triple-en-marcha","post_title":"Retatrutid y el programa TRIUMPH: el agonista triple en marcha","href":"https:\/\/medizinonline.com\/es\/retatrutid-y-el-programa-triumph-el-agonista-triple-en-marcha\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/560506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=560506"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/560506\/revisions"}],"predecessor-version":[{"id":560866,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/560506\/revisions\/560866"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/560231"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=560506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=560506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=560506"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=560506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}